Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aerpio Pharmaceuticals, Inc is a biotechnology business based in the US. Aerpio Pharmaceuticals shares (ARPO) are listed on the NASDAQ and all prices are listed in US Dollars. Aerpio Pharmaceuticals employs 12 staff and has a trailing 12-month revenue of around USD$15 million.
|Latest market close||USD$2.06|
|52-week range||USD$0.42 - USD$2.29|
|50-day moving average||USD$1.5268|
|200-day moving average||USD$1.4071|
|Wall St. target price||USD$1.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.275|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||82.30%|
|1 month (2020-12-17)||100.00%|
|3 months (2020-10-15)||51.47%|
|6 months (2020-07-15)||53.73%|
|1 year (2020-01-15)||233.77%|
|2 years (2019-01-15)||-28.72%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$15 million|
|Gross profit TTM||USD$0|
|Return on assets TTM||-5.75%|
|Return on equity TTM||-9.08%|
|Market capitalisation||USD$49.5 million|
TTM: trailing 12 months
There are currently 1.8 million Aerpio Pharmaceuticals shares held short by investors – that's known as Aerpio Pharmaceuticals's "short interest". This figure is 6.2% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Aerpio Pharmaceuticals shares can be evaluated.
Aerpio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerpio Pharmaceuticals shares currently shorted divided by the average quantity of Aerpio Pharmaceuticals shares traded daily (recently around 8.4 million). Aerpio Pharmaceuticals's SIR currently stands at 0.21. In other words for every 100,000 Aerpio Pharmaceuticals shares traded daily on the market, roughly 210 shares are currently held short.
However Aerpio Pharmaceuticals's short interest can also be evaluated against the total number of Aerpio Pharmaceuticals shares, or, against the total number of tradable Aerpio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerpio Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Aerpio Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0175% of the tradable shares (for every 100,000 tradable Aerpio Pharmaceuticals shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aerpio Pharmaceuticals.
Find out more about how you can short Aerpio Pharmaceuticals stock.
We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $0.42 up to $2.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 2.0482. This would suggest that Aerpio Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.